Bionomics to Acquire CRO Neurofit for $1.65M; CNS Tx Development Planned
Bionomics will acquire Neurofit, a French contract research organization, in a €1.25 million ($1.65 million) cash-and-stock transaction expected to close before March 1, the Adelaide, Australia-based company said last week.
Bionomics will pay €1 million in cash and €250,000 in shares for Strasbourg, France-based Neurofit. The company conducts preclinical testing of developmental therapeutics for CNS disorders using cellular and animal models, and lists Novartis, Serono, Boehringer-Ingelheim, and Biogen as clients.
The acquisition will enhance Bionomics’ therapeutic development capacity for CNS disorders, Bionomics said.
Additionally, the acquisition includes intellectual property rights to an animal model of Parkinson’s disease, developed by Institute Pasteur, and other animal models.
Earlier this year, Bionomics inked an agreement with PerkinElmer to collaborate on drug screening programs against ion channel and G-protein coupled receptor targets (see Inside Bioassays, 5/18/2004).
Beckman Coulter, Pion Pen Distribution Pact for Drug Permeability-analysis Instruments
Beckman Coulter has entered into a five-year distribution pact with pION to deliver instruments for the automation of in vitro drug-permeability instruments, Beckman Coulter said last week.
The firms will combine Beckman Coulter’s Biomek FX liquid handling system with pION’s double-sink method for parallel artificial membrane permeability analysis. The new instrument, called Biomek FX-ADME/tox Workstation, is controlled by software developed by Woburn, Mass.-based pION.
Beckman has validated the automated system and will distribute it worldwide. The firms will collaborate on application-specific customer support and training.
Financial terms of the deal were not disclosed.